GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Background/Aims: The aim of this study was to determine the direct role of liraglutide (LG) in adipogenesis and lipid metabolism. Methods: Lipid accumulation was evaluated by oil red O staining, quantitative real-time PCR (qPCR) was performed to determine glucagon-like peptide 1 receptor (GLP-1R), fatty acid synthase (FASN) and adipose triglyceride lipase (ATGL) expression in 3T3-L1 preadipocytes, differentiated adipocytes and in adipose tissues from mice. The effects of LG on 3T3-L1 adipogenesis and lipid metabolism were analyzed with qPCR, Western Blotting, oil red O staining, immunohistochemistry (IHC) and immunofluorescence (IF). All measurements were performed at least three times. Results: LG increased the expression of differentiation marker genes and lipid accumulation during preadipocyte differentiation. In differentiated adipocytes, LG decreased FASN expression, and simultaneously led to CREB phosphorylation and ERK1/2 activation which were abolished by a GLP-1R antagonist, exendin (9-39). LG induced-FASN down-regulation was partially reversed by PKA and ERK1/2 inhibitors. Consistent with above in vitro findings, LG treatment significantly reduced FASN expression in visceral adipose tissues of ob/ob mice, and reduced body weight gain. Conclusion: LG promotes preadipocytes differentiation, and inhibits FASN expression in adipocytes. LG induced down-regulation of FASN is at least partially mediated by PKA and MAPK signaling pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous studies have hinted at a signaling relationship between GLP-1 and lipogenesis, where incretin-based treatments improve lipogenesis through the AMPK activation pathway.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [60]
In the citing paper
“Therapeutic long-acting GLP-1 receptor agonists (GLP-1 RAs) reduce glucose levels, decrease hunger, increase satiety, slow gastric emptying, increase adipogenesis and lipogenesis [122] (potentially improving fat functionality and helping to correct adiposopathy), and decrease hepatic glucose production.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [122]
In the citing paper
“Glucagon-like peptide-1 (GLP-1) is an intestinal peptide secreted by the ileum and large intestine that, after food intake, increases pancreatic insulin release (“incretin”) and decreases glucagon secretion.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [122]
In the citing paper
“Some, but not all, GLP-1 RAs have clinical trial evidence supporting favorable effects on cardiovascular disease (CVD) outcomes [122,[140], [141], [142], [143], [144], [145], [146], [147]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [122]
In the citing paper
“Liraglutide was seen to promote pre-adipocytes differentiation and to inhibit FA synthase in adipose tissues from mice [173].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [173]
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Obesity and Diabetes in the Developing World — A Growing Challenge
Hossain, P., Kawar, B., & El Nahas, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068177 · Cited by 2,200
Cellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123
Fat Mobilization in Adipose Tissue Is Promoted by Adipose Triglyceride Lipase
Zimmermann, R., Strauss, J. G., Haemmerle, G., Schoiswohl, G., Birner-Gruenberger, R., Riederer, M., Lass, A., Neuberger, G., Eisenhaber, F., Hermetter, A., et al. (2004) · Science · doi:10.1126/science.1100747 · Cited by 2,116
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Inhibition of Adipogenesis by Wnt Signaling
Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. L., & MacDougald, O. A. (2000) · Science · doi:10.1126/science.289.5481.950 · Cited by 1,874
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
“Growing in vitro evidence revealed that GLP-1R activation increased the expression of differentiation marker genes such as PPARγ and FABP4 and lipid accumulation during preadipocyte differentiation.(361) Gut-derived GLP-1 also increases adipocyte mass through preadipocyte proliferation and inhibition of apoptosis,(362…”
BackgroundAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“60 Research has extensively examined the combined agonists of GLP-1 and GIP1-RA for their potential impact on diabetes management and weight reduction.”
BackgroundPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“The GLP-1R in adipocytes was reported to activate the AC/cAMP signaling pathway, regulating apoptosis and preadipocyte proliferation through various cell signaling cascades including ERK, PKC and AKT, as well-altering the expression of peroxisome proliferator-activated receptor gamma (PPARγ) and its target genes (142,…”
BackgroundDiabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
Cignarelli, A., Genchi, V. A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.002 · Cited by 161
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Obesity: A neuroimmunometabolic perspective
Larabee, C. M., Neely, O. C., & Domingos, A. I. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0283-6 · Cited by 123
Martins, F. F., Marinho, T. S., Cardoso, L. E. M., Barbosa‐da‐Silva, S., Souza‐Mello, V., Aguila, M. B., & Mandarim‐de‐Lacerda, C. A. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3751 · Cited by 112
“Moreover, GLP‐1R was found in eWAT and sWAT preadipocytes in vitro and differentiated adipocytes ex vivo.(10) In the DIO mouse model,(11) semaglutide reduced plasma lipids, liver steatosis, inflammation, and overall glucose metabolism.”
BackgroundGLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
Self-citationTargeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Meurot, C., Jacques, C., Martin, C., Sudre, L., Breton, J., Rattenbach, R., Bismuth, K., & Berenbaum, F. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.02.001 · Cited by 94
“Furthermore, in 3T3-Ll adipocytes, GLP-1 stimulation improved insulin responsiveness by promoting increased glucose uptake and FA synthesis in adipose cells [80], possibly by CREB phosphorylation and ERK1/2 activation [81].”
BackgroundHammoud, S. H., AlZaim, I., Al-Dhaheri, Y., Eid, A. H., & El-Yazbi, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.707126 · Cited by 87
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Pontes-da-Silva, R. M., Marinho, T. D. S., Cardoso, L. E. M., Mandarim‐de‐Lacerda, C. A., & Águila, M. B. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00955-7 · Cited by 77
“Conversely, unsaturated fatty acids negatively regulate FAS [48].”
BackgroundInfluentialSaulīte, L., Jēkabsons, K., Kļaviņš, M., Muceniece, R., & Riekstiņa, U. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.029 · Cited by 81
Szekeres, Z., Nagy, A., Jahner, K., & Szabados, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158214 · Cited by 77
“Furthermore, GLP-1-R has been found in the epidydimal preadipocytes in vitro and in differentiated adipocytes ex vivo as well [25].”
BackgroundBays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
“…long-acting GLP-1 receptor agonists (GLP-1 RAs) reduce glucose levels, decrease hunger, increase satiety, slow gastric emptying, increase adipogenesis and lipogenesis [122] (potentially improving fat functionality and helping to correct adiposopathy), and decrease hepatic glucose production.”
BackgroundWei, S., Zhang, M., Zheng, Y., & Yan, P. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000492697 · Cited by 70
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Bılgın, E., Venerito, V., & Bogdanos, D. P. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103864 · Cited by 57
Bretón‐Romero, R., Weisbrod, R. M., Feng, B., Holbrook, M., Ko, D., Stathos, M. M., Zhang, J., Fetterman, J. L., & Hamburg, N. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009379 · Cited by 54
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
Yang, Z., Chen, F., Zhang, Y., Ou, M., Tan, P., Xu, X., Li, Q., & Zhou, S. (2024) · MedComm · doi:10.1002/mco2.560 · Cited by 51
“276,277 Liraglutide (Saxenda) and semaglutide (Wegovy) are GLP-1R agonists approved by the United States Food and Drug Administration for obesity treatment in 2014 and 2021, promoting the belief that breakthrough, drug-based management of obesity may be possible.”
BackgroundSelf-citationThe osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts
Pal, S., Maurya, S. K., Chattopadhyay, S., Pal China, S., Porwal, K., Kulkarni, C., Sanyal, S., Sinha, R. A., & Chattopadhyay, N. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.024 · Cited by 46
“Lira has been shown to increase the expression of GLP1R in differentiated 3T3-L1 adipocyte causing inhibition of lipogenesis [31] and in pulmonary pneumocytes resulting in decreased surfactant proteins in diabetic rats [32].”
BackgroundYang, P., Liang, Y., Luo, Y., Li, Z., Wen, Y., Shen, J., Li, R., Zheng, H., Gu, H. F., & Xia, N. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s206867 · Cited by 35
“Glucagon-like peptide-1 (GLP-1) is secreted by intestinal L-cells and is produced through the posttranslational processing of proglucagon in response to nutrient ingestion.(6) Recently, GLP-1 receptors are believed to be expressed on human hepatocytes.”
BackgroundThe Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
“This decreases the expression of fatty acid synthase, an enzyme crucial in lipogenesis [52].”
BackgroundThe Impact of Incretin-Based Medications on Lipid Metabolism
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1815178 · Cited by 33
“A signaling axis between GLP-1 and lipogenesis was suggested by more studies in which incretin-based medications ameliorate lipogenesis via AMPK activation pathway [57, 61].”
BackgroundGLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 34
“On the other hand, they are capable of inducing lipolysis [49, 62], browning AT [63], and differentiating preadipocytes [64, 65].”
BackgroundVaittinen, M., Ilha, M., Herbers, E., Wagner, A., Virtanen, K. A., Pietiläinen, K. H., Pirinen, E., & Pihlajamäki, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110635 · Cited by 33
Modulation of adipose tissue metabolism by microbial-derived metabolites
Liu, W., Ge, Y., Liu, P., Jiang, X. M., & Xin, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1031498 · Cited by 33
The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis
Wang, H., Wang, L., Li, Y., Luo, S., Ye, J., Lu, Z., Li, X., & Lu, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111778 · Cited by 30
Wu, J.-Y., Qian, P., Han, Y., Xu, C., Xia, M., Zhan, P., Wei, J.-W., & Dong, J. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01260-3 · Cited by 23
“Previous studies have shown that GLP1 receptor agonists (GLP-1RAs) reduce plasma triglyceride levels and hepatic lipid stores [31 – 33] and that GLP1 directly inhibits lipogenesis in mature adipocytes [34].”
Hu, N., Zeng, X., Tang, F., & Xiong, S. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.053 · Cited by 26
Qin, H., Song, Z., Zhao, C., Yang, J., Xia, F., Wang, L., Ali, A., & Zheng, W. (2022) · Nutrients · doi:10.3390/nu14061287 · Cited by 29
“For example, some studies have demonstrated that the downregulation of FASN in adipocytes is partially mediated by the PKA and MAPK signaling pathways [35,36].”
BackgroundLi, P., Zhu, L., Yang, X., Li, W., Sun, X., Yi, B., & Zhu, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27940 · Cited by 25
Stafeev, I., Agareva, M. Y., Michurina, S. S., Tomilova, A., Shestakova, E. A., Zubkova, E., Sineokaya, M. S., Ratner, E. I., Menshikov, M. Y., Parfyonova, Y. V., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176476 · Cited by 23
Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats
Model, J. F. A., Lima, M. V., Ohlweiler, R., Vogt, É. L., Rocha, D. S., de Souza, S. K., Türck, P., Araújo, A. S. D. R., & Vinagre, A. S. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111158 · Cited by 24
Effects of antidiabetic drugs on epicardial fat
Xourgia, E., Papazafiropoulou, A. K., & Melidonis, A. J. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i9.141 · Cited by 22
DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment
Guo, X., Feng, H., Cai, L., Zheng, J., & Li, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117464 · Cited by 22
Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism
Model, J. F. A., Normann, R. S., Vogt, É. L., Dentz, M. C. V., de Amaral, M., Xu, R., Bachvaroff, T. R., Spritzer, P. M., Chung, J. S., & Vinagre, A. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116623 · Cited by 22
Kang, L., Li, X., Zhao, X., Liu, T., Jin, Y., & Duan, Y. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.143677 · Cited by 19
Neuro-immune-metabolism: The tripod system of homeostasis
Deshpande, D., Fuchs, L., & Klose, C. S. N. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.10.001 · Cited by 21
Bakkar, N. Z., AlZaim, I., & EL‐Yazbi, A. F. (2022) · Clinical Science · doi:10.1042/cs20220404 · Cited by 20
Liu, H., Zhan, Y.-L., Luo, G., Zou, L., Li, Y., & Lu, H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s253097 · Cited by 19
GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
Li, H., Donelan, W., Wang, F., Zhang, P., Yang, L., Ding, Y., Tang, D., & Li, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.777026 · Cited by 21
“CREB is an important transcription factor known to mediate multiple actions of GLP-1 in pancreatic islets (Shin et al., 2014; Chen et al., 2017).”
BackgroundChen, H., Cao, T., Zhang, B., & Cai, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097284 · Cited by 18
“The binding of GLP to GLP-1R in adipocytes activates the adenylyl cyclase (AC)/cAMP signaling pathway, regulates the apoptosis and proliferation of preadipocytes through various cellular signaling pathways, such as extracellular signal–regulated kinase (ERK), protein kinase C (PKC), and AKT, and alters the expression…”
BackgroundLi, Y., Sun, W., Liu, H., & Ruan, X. Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101761 · Cited by 22
“41 In our study, the expression of ATGL in adipose tissue increased with tirze-patide treatment, leading to increased lipolysis.”
Zhang, N., Zhou, H., Xu, Y., Zhang, Y., Yu, F., Gui, L., Zhang, Q., & Lu, Y. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112225 · Cited by 16
Self-citationForst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Basdas, R., Martínez-Cereijo, J. M., Fernández, Á. L., Reija, L., Cabaleiro, A., Bravo, S. B., González‐Juanatey, J. R., & Eirás, S. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.03.009 · Cited by 16
Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Gao, L., Yang, K., Zhao, Y., Zhang, J., Jiang, S., Zhang, R., He, W., Zhao, Y., Ye, Q., & Xu, G. (2025) · Science Advances · doi:10.1126/sciadv.adv3201 · Cited by 14
“It can be involved in lipid metabolism by inhibiting fat synthesis ( 35 ), promoting fat differentiation ( 10 ), enhancing cholesterol metabolism ( 36 ), and promoting fat browning ( 37 ).”
Model, J. F. A., Lima, M. V., Ohlweiler, R., Sarapio, E., Vogt, É. L., Rocha, D. S., de Souza, S. K., & Vinagre, A. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119586 · Cited by 15
English, A. R., Craig, S. L., Flatt, P. R., & Irwin, N. (2020) · Biological Chemistry · doi:10.1515/hsz-2020-0195 · Cited by 14
Oral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Suraiya, S., Choi, Y. B., Park, H. D., Jang, W. J., Lee, H. H., & Kong, I. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.02.043 · Cited by 12
Wang, Z., Xu, Q., Hou, L., He, Z., Christian, M., & Dai, X. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2500675 · Cited by 15
“After release, GLP-1 enters the circulation and is transported through the bloodstream to adipose tissue, where it further binds to the GLP-1 receptor (GLP-1R) on the surface of adipocytes, leading to the inhibition of lipogenesis and thermogenesis in BAT and epididymal WAT (Chen et al. 2017).”
Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism
Dasso, M. E., Centola, C. L., Galardo, M. N., Meroni, S. B., & Riera, M. F. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0274 · Cited by 10
Do anti-obesity medical treatments have a direct effect on adipose tissue?
Vergès, B. L. (2024) · Annales d Endocrinologie · doi:10.1016/j.ando.2024.05.021 · Cited by 10
Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome
Ferdous, J., Hossain, M., Faika, M. J., Begum, M., Mahjabeen, S., Jahan, I., Khan, M., & Hossain, M. (2025) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20251002.12 · Cited by 9
Kruglikov, I. L. (2025) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.70584 · Cited by 8
“Protein expression of GLP-1Rs during 3 T3-L1 adipogenesis demonstrated a distinctly transitory behavior, increasing during the early stages and substantially decreasing during the late stages of differentiation [12].”
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
“demonstrated that GLP-1 RA significantly reduced the expression of fatty acid synthase (FAS), a key enzyme in de novo lipogenesis [131].”
BackgroundHe, X., Guan, H., Liang, W., Huang, Z., Xu, L., Zhang, P., Xu, F. L., & Li, Y. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0024-2 · Cited by 8
The Link between Salivary Amylase Activity, Overweight, and Glucose Homeostasis
Erta, G., Gersone, G., Jurka, A., & Tretjakovs, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189956 · Cited by 7
“…reducing the release of free fatty acids into circulation [24,25] This helps prevent lipid overload in tissues and organs, including adipocytes [26,27] • Anti-inflammatory Effects: GLP-1 exhibits anti-inflammatory properties in adipocytes and adipose tissue by reducing the production of…”
BackgroundBenefits of GLP-1 Mimetics on Epicardial Adiposity
Yaribeygi, H., Maleki, M., Nasimi, F. S., Jamialahmadi, T., Stanford, F. C., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230113110431 · Cited by 7
Selim, D. H., Mokhlis, H. A., Elsayed, A. M., Shatat, A.-A. S., Salama, S. A., & Ismail, R. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03789-6 · Cited by 6
“…differentiation and lipid metabolism including protein kinase A (PKA), mitogen-activated protein kinase (MAPKs), phosphorylation of cAMP response element binding protein (pCREB), and extracellular signal-regulated kinase (ERKs) in a dose-and time-course-dependent manner (Chen et al. 2017).”
Di, W., Bai, X., Tian, S., Zhao, L., Cao, X., Hao, Y., & Zhai, Z. (2025) · 3 Biotech · doi:10.1007/s13205-025-04465-5 · Cited by 6
“This process helps reduce triglyceride accumulation within fat cells, leading to a reduction in adipocyte size (Chen et al. 2017).”
Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
Kourtidou, C., & Τζιόμαλος, Κ. (2023) · Biomedicines · doi:10.3390/biomedicines11020496 · Cited by 7
“These studies showed the potential relationship between GLP-1 agonism and inhibition of fatty acid synthase expression [31], brown adipose tissue thermogenesis mediated by AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT-1) [32,34] and lipolysis and fatty acid oxidation mediated by SIRT-1 [33].”
Fejes, R., Kádár, C., Kovács-Huber, R., Taybani, Z. J., Juhász, L., Rutai, A., & Tallósy, S. P. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/9141564 · Cited by 5
Mamontova, E. D., Michurina, S. S., Stafeev, I., Sorkina, E., Sklyanik, I. A., Koksharova, E., Menshikov, M. Y., Shestakova, M. V., & Parfyonova, Y. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s000629792103010x · Cited by 5
Gao, H., Song, Z., Zhao, Q., Wu, Y., Tang, S., Alahdal, M., Shen, Y., Xing, Y., Pan, Y., Li, J., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491978 · Cited by 5
Self-citationMa, B., Liu, Y., ZHANG, H., Fang, Y., Xue, Y., Xue, J., Jiang, Z., Zhou, T., Hao, Y., Xie, F., et al. (2025) · Advanced Science · doi:10.1002/advs.202517672 · Cited by 5
“GLP-1 enhances insulin sensitivity while simultaneously stimulating preadipocyte differentiation [ 35–38 ].”
Self-citationGLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats
Morais, T., Pereira, S. S., Andrade, S., Neves, D., Guimarães, M., Nora, M. C., Carreira, M. C., Casanueva, F. F., & Monteiro, M. P. (2023) · Biomedicines · doi:10.3390/biomedicines11051322 · Cited by 4
“GLP-1 downregulates adipocytes fatty acid synthase [54], which is essential for fatty acid synthesis.”
BackgroundThermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
“Additionally, preclinical studies show that GLP-1/GLP-1R signaling promotes preadipocyte proliferation and differentiation while lowering glycemia and attenuating weight gain [27,28], suggesting metabolically favorable adipose remodeling rather than net adipose accumulation.”
Aligita, W., Muhsinin, S., Wijaya, K., Artarini, A., & Adnyana, I. K. (2020) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2020.1315555 · Cited by 3
Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes
Lui, A., Patel, R. S., Krause‐Hauch, M., Sparks, R. P., & Patel, N. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814324 · Cited by 4
“GLP1-GLP1R signaling in adipocytes is also shown to be mediated via the PKA and MAPK pathways in adipocytes [75,77].”
BackgroundEffects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
Mamontova, E. D., Michurina, S. S., Стафеев, Ю. С., Sorkina, E., Скляник, И. А., Koksharova, E., Menshikov, M., Shestakova, M. V., & Парфёнова, Е. В. (2021) · Biochemistry (Moscow) · doi:10.31857/s032097252103009x · Cited by 1
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Gabr, N. M., & Fouda, A. (2018) · Al-Azhar Medical Journal · doi:10.12816/0052811 · Cited by 1
“Both effects lead to inhibition of lipolysis, reduction of free fatty acids as well as lipogenesis in adipose tissue (Chen et al., 2017).”
BackgroundClinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China
Hong, T., Liu, J., & Wei, R. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00030 · Cited by 1
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Xie, J., Hong, Z., Mao, J., Peng, L., Bai, Y., Sheng, J., & Tian, Y. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250328
GLP-1RA: New Hope in Obesity Therapy
Zhang, D., & Lu, H. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.132035
Hara, S., Yamada, C., Suehiro, D., Fukami, K., Nakagawa, T., & Shimada, M. (2025) · Journal of Oleo Science · doi:10.5650/jos.ess25036
Yang, R., Lin, Y.-C., Lan, K., Wang, C., Tzeng, H.-P., Chang, T.-Y., Chan, D., & Liu, S. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119523
Kunrade, L. (2020) · E-resource repository of the University of Latvia (University of Latvia)
Chen, X., Zhang, B., Yang, M., Zhuang, Y., Liao, X., & Shi, G. (2026) · Neurocritical Care · doi:10.1007/s12028-025-02446-3
“Studies have shown that the level of cleaved caspase-3 were significantly reduced in GLP-1 receptor knockdown cells, which were thereby protected from apoptosis [29].”
Peptide-functionalized nanoemulsions with exendin-4 as a model ligand
Holler, N., Gesslbauer, B., Tam‐Amersdorfer, C., Letofsky‐Papst, I., Mayrhofer, C., Andreae, F., & Zimmer, A. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100598
“In contrast, when applied from day 2 onward, exendin-4 reduced lipid accumulation, reflecting stage-dependent effects of GLP-1R signaling (Chen et al., 2017; Yang et al., 2013).”
InfluentialMalbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss
Gupta, A. K., Kaur, J., Piguet, V., & Mirmirani, P. (2026) · Biology · doi:10.3390/biology15181642
“Across the SURMOUNT clinical trial program, alopecia occurred more frequently among tirzepatide-treated participants than placebo-treated controls (5.22% [99/1896] versus 0.93% [6/643] in SURMOUNT-1 and 6.97% [20/287] versus 1.37% [4/292] in SURMOUNT-3) [42,43].”
InfluentialSong, H., Li, S., Lin, J., Hu, Y., Shi, H., Wang, X., Tang, F., Gao, L., Chen, Z., Zhang, S., et al. (2026) · Environment International · doi:10.1016/j.envint.2026.110534
Self-citationLiraglutide reduces lipid accumulation in human orbital fibroblasts in Graves’ orbitopathy
Shih, C.-W., Shih, S.-R., Wei, Y.-H., LIN, C.-H., Shu-Lang, L., Chou, T.-A., Chu, I., Chen, H.-J., Liao, N.-L., & Tsai, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1914378
“Previous studies have shown that GLP-1 – related effects may occur through canonical GLP-1R-dependent pathways involving PKA, MAPK, Akt, and PKC signaling (13, 15, 16).”
Metadata
- Authors
- Chen, J., Zhao, H., Ma, X., Zhang, Y., Lu, S., Wang, Y., Zong, C., Qin, D., Wang, Y., Yingfeng Yang, Y., Wang, X., & Liu, Y.
- Affiliations
- Shandong University (CN)
- Qingdao Municipal Hospital (CN)
- Second Hospital of Shandong University (CN)
- ORCID
- Venue
- Cellular Physiology and Biochemistry
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 42
- Issue
- 3
- Pages
- 1165-1176
- ISSN
- 1015-8987 (ISSN-L)
- 1421-9778
- OpenAlex
- W2727734358
- Cited by
- 94
- References
- 48
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 12 · 2023: 8 · 2022: 12 · 2021: 13 · 2020: 6 · 2019: 5 · 2018: 11
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Cellular Physiology and Biochemistry (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- liraglutide, GLP-1 receptor, adipogenesis, lipogenesis, fatty acid synthase, adipose triglyceride lipase, CREB phosphorylation, ERK signaling, PKA signaling, 3T3-L1 preadipocytes, visceral adipose tissue, ob/ob mice, weight gain, lipid metabolism
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Hypoglycemic Agents, Signal Transduction, Down-Regulation, Adipocytes, 3T3-L1 Cells, Lipogenesis, Adipogenesis, Mice, Glucagon-Like Peptide 1, Fatty Acid Synthase, Type I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.